Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
stock ticker
|
| gptkbp:businessModel |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:J.J._Finkelstein
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
development of therapeutic peptides
treatment of cardiovascular diseases treatment of central nervous system injuries treatment of ophthalmic diseases |
| gptkbp:foundedYear |
1982
|
| gptkbp:headquartersLocation |
gptkb:Rockville,_Maryland,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
RGRX
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mainProductCandidate |
Thymosin beta 4 (Tβ4)
|
| gptkbp:refersTo |
RegeneRx Biopharmaceuticals, Inc.
|
| gptkbp:stockExchange |
gptkb:OTC_Markets
|
| gptkbp:website |
https://www.regenerx.com/
|
| gptkbp:bfsParent |
gptkb:RegeneRx_Biopharmaceuticals
|
| gptkbp:bfsLayer |
7
|